Topic:

M&A

Latest Headlines

Latest Headlines

InterMune buyout rumors resurface, with Roche, Sanofi on the short list

InterMune's promising treatment for a rare lung disease has put it in Big Pharma's crosshairs, according to a report, news that sent the biotech's shares soaring as much as 20% on Wednesday.

When will Merck KGaA take the M&A plunge?

Merck KGaA is talking up deals again, pointing to its healthy cash reserves and saying it can well afford a blockbuster buyout to bolster its pipeline. But that's been the story for nearly a year, so what's the German giant waiting on?

Valeant's No. 3 shareholder: We don't need Allergan

A top Valeant shareholder isn't saying the company can't win its hostile $53 billion takeover battle for Allergan. It's just saying it doesn't need to.

UniQure bets on a gene therapy for heart failure

After making international headlines with the West's first approval for a gene therapy, pioneering biotech uniQure is working to flesh out its pipeline of one-time treatments, buying into an early-stage shot at heart failure that could put its technology on the biggest stage yet.

Med tech M&A speculation swirls around Nobel, CareFusion

Dental company Nobel Biocare is reported to have attracted some suitors in its quest to sell itself, while speculation arises that healthcare analytics and management company CareFusion could be next up for a big M&A deal.

Will threats of an inversion crackdown quash pharma's foreign-deal bonanza?

U.S. legislators are threatening to make it more difficult for American companies to take off for a new home in a tax-advantaged country. But what's in store for drugmakers who have already wrapped their own so-called tax inversion deals--and those who are planning them for the future?

Med tech M&A gets much, much bigger during the first half

Not only are we going to walk you through the top med tech M&A deals of the first half of 2014, but we will take a look back to how the acquisitions from the first half of 2013 are working out and if the acquirer got exactly what they bargained for.

Deal-minded Venn buys another CRO

CRO Venn Life Sciences is spreading its reach around Europe through M&A, buying up a French outsourcer to bolster its abilities in data management.

Boston Scientific down on disclosure of subpoena about Bridgepoint acquisition

A Securities and Exchange Commission filing from Aug. 6 disclosed that Boston Scientific received a subpoena from the U.S. Attorney for the District of New Jersey regarding its acquisition of Bridgepoint Medical, leading to a sharp decline in trading. 

Pharma shares sink as U.S. threatens tax-inversion crackdown

U.S. drugmakers have embraced the tax inversion strategy with open arms as of late, buying up foreign companies right and left and hauling overseas to take advantage of their lower rates. But U.S. officials are looking to stop them in their tracks--an intent that has some pharma investors worried.